CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,520 enrolled
Drug / intervention
ForeseeHome AMD Monitoring Deviceother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01103505
NCT01103505N/ACompleted
CompareCT.gov

The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)

Notal Vision Ltd.·interventional·Posted Apr 14, 2010·Updated Jul 30, 2019

In Brief

A clinical study evaluating ForeseeHome AMD Monitoring Device for Age Related Macular Degeneration. Completed, enrolled 1,520 participants across 38 sites.

Detailed Summary

The overall objective of this two arm randomized clinical trial (RCT) is to determine if home monitoring using the comprehensive visual field and telemedicine solution based on the ForeseeHome device in AREDS2 improves detection of progression to choroidal neovascularization (CNV) when compared with standard care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge Related Macular Degeneration
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 14, 2010
Enrollment StartMay 1, 2010
Primary CompletionOct 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 16.2 years ago

Interventions

ForeseeHome AMD Monitoring Deviceother

Earlier detection of progression from intermediate dry age-related macular degeneration to CNV between routine eye exams through home diagnostic testing with the ForeseeHome AMD Monitoring device